English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Phosphatidylinositol 3-kinase (PI3K) is an essential target in lymphoid tumors therapy.Copanlisib is a novel class of medication that targets PI3K and used for the treatment of relapsing orrefractory B-cell lymphomas.Case Presentation: A 42-year-old woman presents to our hospital for worsening abdominal pain.Examination pertinent for axillary lymphadenopathy, and abdominal ascites. CT chest, abdomen and pelvisreported multiple lung nodules, pleural effusions, extensive retroperitoneal lymphadenopathy, andperitoneal carcinomatosis. Lymph node and bone marrow biopsies confirmed B-cell follicular lymphomaand fluorescent in situ hybridization (FISH) testing was positive for translocation t(14:18). Her disease wasrefractory to multiple chemotherapy regimens. Thus, initiated copanlisib therapy with a remarkableresponse, but the patient developed a diffuse maculopapular rash and skin biopsy-proven to be drug rash.Therefore, copanlisib was discontinued.Conclusion: Here, we report a case of a middle-aged woman who developed a rash after the fifth cycle ofcopanlisib therapy. This case report will create awareness of evolving possible side effects in this novelchemotherapeutic agent.

Copanlisib-Associated Skin Toxicity: A Peculiar Case of Copanlisib-Induced Skin Rash in a Patient with Refractory Follicular Lymphoma